ALY-601

ALY-601 is a topical peptide therapeutic currently in Phase 1/2 development by Alys Pharmaceuticals for the treatment of vitiligo. The drug is formulated using the proprietary STAR* (Surface Tension-Activated Release) particle suspension gel technology. This delivery platform utilizes microscopic, star-shaped particles that, when applied to the skin, create temporary micro-channels in the stratum corneum to facilitate the penetration of large molecules, such as peptides, into the deeper layers of the skin. By enabling topical delivery of a peptide active ingredient, ALY-601 aims to provide localized efficacy while minimizing the systemic exposure and side effects associated with oral or injectable treatments. The specific biological target of the peptide has not been publicly disclosed by the developer.